½ÃÀ庸°í¼­
»óǰÄÚµå
1577057

Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °Ë»ç ½ÃÀå, ½ÃÀå µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Helicobacter Pylori Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 110 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®(H. Pylori) °Ë»ç ½ÃÀåÀº 2023³â¿¡ 4¾ï 8,300¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£ ÁßÀÇ ¼ºÀå·üÀº 6.8%·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

ÀÌ °°Àº ¼ºÀåÀº À§À庴 À¯º´·ü Áõ°¡, ÇöÀå °Ë»ç(PoC) ¼ö¿ä Áõ°¡, ºñħ½ÀÀû Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °Ë»ç µµÀÔ È®´ë¿¡ ÈûÀÔ¾î ÀÌ·ïÁ³½À´Ï´Ù.

½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀº Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °¨¿°À¸·Î ÀÎÇÑ À§±Ë¾ç ȯÀÚ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ½ºÆ®·¹½º, Èí¿¬, ºñ½ºÅ×·ÎÀ̵强 Ç׿°Áõ¾à(NSAIDs) °ú´Ù º¹¿ë µîÀÌ À§±Ë¾ç ¹ß»ý·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ¼ÒÈ­±âÇÐȸ(AGA)¿¡ µû¸£¸é À§±Ë¾ç ȯÀÚÀÇ 70-90%¿¡¼­ Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®ÀÌ Á¸ÀçÇϸç, ÀÌ´Â ±Ë¾ç °ü·Ã Áúȯ °ü¸®¿¡ ÀÖÀ¸¸ç, °Ë»çÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

H. pylori °Ë»ç¿¡´Â ¼ÒÈ­°ü³» Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®ÀÇ Á¸À縦 °¨ÁöÇÏ´Â ´Ù¾çÇÑ Áø´Ü ¹æ¹ýÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ¹ÚÅ׸®¾Æ´Â ¼ÒÈ­¼º ±Ë¾ç, ¸¸¼º À§¿° ¹× °æ¿ì¿¡ µû¶ó À§¾Ï°ú °°Àº Áúº´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. Á¤È®ÇÑ °Ë»ç´Â °¨¿° Áø´Ü, Ä¡·á Áöħ ¹× Ä¡·á È¿°ú ¸ð´ÏÅ͸µ¿¡ µµ¿òÀÌ µË´Ï´Ù.

½ÃÀåÀº °Ë»ç À¯Çüº°·Î ħ½ÀÀû °Ë»ç¿Í ºñħ½ÀÀû °Ë»ç·Î ±¸ºÐµÇ¸ç, 2023³â ½ÃÀå Á¡À¯À²Àº ºñħ½ÀÀû °Ë»ç°¡ 56.6%·Î ¾ÐµµÀûÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ä¼ÒÈ£±â°Ë»ç(UBT)³ª ´ëº¯Ç׿ø°Ë»ç(SAT)¿Í °°Àº ºñħ½ÀÀû °Ë»ç´Â ºÒÆíÇÔÀÌ Àû°í °á°ú°¡ ºü¸£¸ç ¸ðµç ¿¬·ÉÃþ¿¡ ÀûÇÕÇÏ´Ù´Â ÀåÁ¡À¸·Î ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡À¸·Î ÀÎÇØ ºñħ½ÀÀû °Ë»ç´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµé »çÀÌ¿¡¼­ Àαâ ÀÖ´Â ¼±ÅÃÀÌ µÇ°í ÀÖÀ¸¸ç, ÀÌ ºÐ¾ßÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº °Ë»ç ¹æ¹ýº°·Î PoC °Ë»ç¿Í ½ÇÇè½Ç ±â¹Ý °Ë»ç·Î ºÐ·ùµÇ¸ç, ÈÄÀÚ°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç 2023³â ½ÃÀå ±Ô¸ð´Â 3¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ¹× È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø¹ý(ELISA)°ú °°Àº ½ÇÇè½Ç ±â¹Ý °Ë»ç´Â ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Á¦°øÇÏ¿© Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °¨¿°ÀÇ Á¤È®ÇÑ Áø´Ü°ú Ç×»ýÁ¦ ³»¼º ¸ð´ÏÅ͸µ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµº°·Î´Â Áø´Ü ½ÇÇè½ÇÀÌ 2023³â ½ÃÀåÀ» Àå¾ÇÇϰí 2032³â¿¡´Â 3¾ï 9,090¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç½ÇÀº Àü¹®ÀûÀÎ °Ë»ç ¼­ºñ½º¸¦ Á¦°øÇÏ¿© Àû½Ã¿¡ Áø´ÜÇϰí È¿°úÀûÀÎ Ä¡·á °èȹÀ» ¼¼¿ì´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

ºÏ¹Ì Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °Ë»ç ½ÃÀåÀº 2023³â 1¾ï 7,010¸¸ ´Þ·¯ ±Ô¸ð·Î ¿¬Æò±Õ 4.3%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº À§¾Ï À¯º´·ü Áõ°¡¿Í Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °¨¿°¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ±×¸®°í Áø´Ü ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½Å¿¡ ÈûÀÔÀº °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • À§±Ë¾çÀÇ À¯º´·ü »ó½Â
      • ¸®½ºÅ©¸¦ °¡Áø °í·ÉÀÚ Àα¸ÀÇ Áõ°¡
      • POC(Point of Care) °Ë»ç±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • ºñħ½ÀÀû Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °Ë»çÀÇ Ã¤Åà Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ħ½ÀÀû °Ë»ç¿ë ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·
      • Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °¨¿°¿¡ °üÇÑ ÀÎ½Ä ºÎÁ·
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • »óȯ ½Ã³ª¸®¿À
  • ±ÔÁ¦ »óȲ
  • ±â¼ú »óȲ
  • °¡°Ý ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®
  • °¸ ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : °Ë»ç À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ħ½À¼º
    • Á¶Á÷ °Ë»ç
    • ½Å¼Ó ¿ì·¹¾ÆÁ¦ °Ë»ç
    • HP ¹è¾ç
  • ºñħ½ÀÀû
    • Ç÷ûÇÐÀû °Ë»ç
    • ¿ä¼Ò È£±â ½ÃÇè
    • º¯(Stool/fecal) Ç׿ø °Ë»ç

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : °Ë»ç¹ýº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • POC(Point of Care) °Ë»ç
  • ½ÇÇè½Ç ±â¹Ý °Ë»ç

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ »ç¿ëº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Áø·á¼Ò
  • Áø´Ü ½ÇÇè½Ç
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Advance Pharma
  • Avanos Corporate
  • Biohit Oyj
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Epitope Diagnostics
  • Gulf Coast Scientific
  • Laboratory Corporation of America, Inc.
  • Medline Industries
  • Meridian Biosciences, Inc.
  • Quidel Corporation
  • TECHLAB, Inc
  • Thermo Fischer Scientific Corporation
KSA 24.11.06

The Global Helicobacter Pylori (H. Pylori) Testing Market was valued at USD 483 million in 2023, with a projected growth rate of 6.8% over the forecast period. This growth is driven by the increasing prevalence of gastrointestinal disorders, a rising demand for point-of-care (PoC) testing, and the growing adoption of non-invasive H. pylori tests.

A major factor contributing to the market's expansion is the rise in gastric ulcer cases, often caused by H. pylori infections. Factors such as stress, smoking, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) contribute to the increased incidence of gastric ulcers, fueling the demand for diagnostic testing. According to the American Gastroenterological Association (AGA), H. pylori is present in 70-90% of patients with peptic ulcers, highlighting the critical role of testing in managing ulcer-related conditions.

H. pylori testing encompasses various diagnostic procedures to detect the presence of the bacterium in the gastrointestinal tract. This bacterium is associated with conditions such as peptic ulcers, chronic gastritis, and, in some cases, gastric cancer. Accurate testing aids in diagnosing infections, guiding treatment, and monitoring therapy effectiveness.

The market is segmented by test type into invasive and non-invasive tests, with the non-invasive segment holding a dominant 56.6% market share in 2023. Non-invasive tests like the urea breath test (UBT) and stool antigen test (SAT) are preferred for their minimal discomfort, rapid results, and suitability for all age groups. These advantages make non-invasive tests a popular choice among healthcare providers, contributing to segment growth.

The market is further categorized by method into PoC and laboratory-based tests, with the latter accounting for the largest market share, valued at USD 300.6 million in 2023. Laboratory-based tests, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), offer high sensitivity and specificity, playing a crucial role in accurately diagnosing H. pylori infections and monitoring antibiotic resistance.

In terms of end use , diagnostic laboratories dominated the market in 2023 and are expected to reach USD 390.9 million by 2032. These laboratories offer specialized testing services, aiding in timely diagnoses and effective treatment planning.

The North American H. pylori testing market was valued at USD 170.1 million in 2023, with a projected CAGR of 4.3%. The region's market growth is driven by the rising prevalence of gastric cancers and growing awareness of H. pylori infections, supported by ongoing innovations in diagnostic technologies.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rise in prevalence of gastric ulcer
      • 3.2.1.2 Increasing geriatric population at risk
      • 3.2.1.3 Growing demand for point-of-care testing devices
      • 3.2.1.4 Rising adoption of non-invasive H. pylori testing
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Lack of skilled professionals for invasive testing
      • 3.2.2.2 Lack of awareness regarding H. pylori infection
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Technology landscape
  • 3.7 Pricing analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Gap analysis
  • 3.11 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Invasive
    • 5.2.1 Histology
    • 5.2.2 Rapid urease test
    • 5.2.3 HP culture
  • 5.3 Non-invasive
    • 5.3.1 Serologic test
    • 5.3.2 Urea breath test
    • 5.3.3 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Point of care (POC) tests
  • 6.3 Laboratory based tests

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Diagnostic laboratories
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Advance Pharma
  • 9.3 Avanos Corporate
  • 9.4 Biohit Oyj
  • 9.5 bioMerieux SA
  • 9.6 Bio-Rad Laboratories, Inc.
  • 9.7 Cardinal Health, Inc.
  • 9.8 Epitope Diagnostics
  • 9.9 Gulf Coast Scientific
  • 9.10 Laboratory Corporation of America, Inc.
  • 9.11 Medline Industries
  • 9.12 Meridian Biosciences, Inc.
  • 9.13 Quidel Corporation
  • 9.14 TECHLAB, Inc
  • 9.15 Thermo Fischer Scientific Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦